← FDA DRUG APPROVALS

FDA ANDA · ANDA070885

BETAMETHASONE DIPROPIONATE

Sponsor: ACTAVIS MID ATLANTIC

APPLICATION
ANDA070885
TYPE
ANDA
ORIGINAL APPROVAL
1987-02-03
LATEST ACTION
2003-01-22
ROUTE
TOPICAL
DOSAGE FORM
CREAM
MARKETING STATUS
Prescription

Products

BETAMETHASONE DIPROPIONATEPrescription
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE · CREAM · TOPICAL

Approval history

2003-01-22Labeling · Supplement 15AP
2001-05-30Manufacturing (CMC) · Supplement 14AP
2000-12-29Manufacturing (CMC) · Supplement 13AP
1996-08-08Manufacturing (CMC) · Supplement 9AP
1996-08-08Manufacturing (CMC) · Supplement 7AP
1996-08-08Manufacturing (CMC) · Supplement 10AP
1996-08-08Manufacturing (CMC) · Supplement 8AP
1996-08-08Manufacturing (CMC) · Supplement 6AP
1996-06-28Manufacturing (CMC) · Supplement 11AP
1996-02-07Manufacturing (CMC) · Supplement 5AP
1995-11-22Manufacturing (CMC) · Supplement 4AP
1993-01-29Manufacturing (CMC) · Supplement 3AP
1989-09-11Manufacturing (CMC) · Supplement 2AP
1989-02-06Labeling · Supplement 1AP
1987-02-03OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →